Tower Semiconductor heads into September having shed 6.4% on the week, with options traders abruptly turning more cautious and the CEO having banked a sizeable sum near the stock's recent peak.
The sharpest signal this week came from options. The put/call ratio closed at 0.90 on Tuesday — almost two standard deviations above its 20-day average of 0.74, its most defensive reading in months. That jump is notable because the ratio had been tracking in a tight band around 0.75 for most of August. The single-session spike to 0.90 after sitting at 0.56 the day before suggests hedging demand arrived quickly, in step with a stock that fell nearly 3% on the day. The PCR remains well below its 52-week high of 1.16, so conditions are cautious rather than panicked, but the shift in tone is clear.
The borrow market tells a different story — one of low conviction on the short side. Short interest slipped to roughly 2.2% of the free float, down nearly 4% on the week and about 12% over the past month. That is a low and falling number. Availability in the lending pool is exceptionally loose at over 2,000%, meaning there are many more shares available to borrow than are currently on loan. Cost to borrow holds near 0.51% — barely off the floor. The lending market is not set up for squeeze dynamics; shorts have been quietly covering, not building.
The analyst backdrop is broadly constructive, though two fresh initiations highlight a growing spread in conviction. Stifel initiated this week with a Buy and a $270 target — essentially in line with where the stock traded, implying little near-term upside at current levels. That contrasts with Bank of America, which launched coverage in August with a Buy and a $367 target, nearly 85% above Tuesday's close of $199. The consensus rating remains Buy across six analysts, with a mean price target of $314.91. Bulls point to Tower's diversified specialty foundry platform, AI data center connectivity exposure, and a 30-day EPS momentum factor score ranking in the 84th percentile. Bears flag heavy customer concentration — the top five accounted for close to half of revenue in recent years — and a valuation that is not obviously cheap, with EV/EBITDA near 22.5x and a PE around 39x trailing earnings.
The ownership picture adds an interesting subplot. The most recent institutional flow shows Israeli funds — Migdal, Clal, Menora, Harel, and Phoenix — collectively holding or recently filing around the stock as significant passive holders, reflecting Tower's dual-listed heritage. T. Rowe Price added roughly 261,000 shares in Q2, lifting its stake to 6.2% of shares. Jane Street added 1.7 million shares, though as a market-maker that is more likely a hedging position than a directional bet. On the insider side, CEO Russell Ellwanger sold a combined ~$25 million in stock on August 11, when shares were trading above $244. That was a cluster of transactions filed the same day and executed at prices meaningfully above where the stock trades now. The data source does not flag a 10b5-1 plan, though it is worth noting Tower is incorporated in Israel and the data reflects vendor-reported trades; investors may want to check the underlying SEC filings directly for plan disclosures.
The most recent earnings print, from early August, saw the stock drop nearly 10% the following day before recovering 6.5% over the subsequent week — a pattern of initial sell-the-news followed by a rebound. The next scheduled earnings date is November 12. Between now and then, the watch items are whether the options PCR normalises back toward its August range as the week-end flows clear, whether the CEO's selling cluster proves a one-off or continues, and how the stock behaves relative to close peers: NVMI dropped 8.3% on the week, FORM fell 11.4%, and DIOD slid 6.3%, suggesting the pressure on TSEM this week was sector-wide rather than company-specific.
See the live data behind this article on ORTEX.
Open TSEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
